TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22392835

Group type: EXPERIMENTAL
Intervention: 100% oxygen inhalation at a rate of 15 L/min for 3 min
Number of subjects: 179

Group type: COMPARATOR
Intervention: Control group (noncirrhotic patients)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Child‐Pugh class A
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Child‐Pugh class B/C
Number of subjects: 179
Study: 19939723

Group type: EXPERIMENTAL
Intervention: Spinal stabilisation exercises
Number of subjects: 9
Study: 18290881

Group type: EXPERIMENTAL
Intervention: 16-slice multidetector computed tomography (MDCT)
Number of subjects: 30
Study: 15859361

Group type: EXPERIMENTAL
Intervention: Celecoxib (CE) 200 mg administered in refracted doses
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 11836044

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg/day
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conjugated equine estrogens 0.6 mg plus sequential medrogestone 5 mg (CEE/M)
Number of subjects: 72
Study: 10881067

Group type: EXPERIMENTAL
Intervention: Proximal splenorenal shunt (PSS)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Distal splenorenal shunt (DSS)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Esophagogastric devascularization with splenectomy (EGDS)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Differential grading analysis between PSS and EGDS
Number of subjects: 73

Group type: COMPARATOR
Intervention: Differential grading analysis between proximal and distal splenorenal shunts
Number of subjects: 73
Study: 7538237

Group type: EXPERIMENTAL
Intervention: Bicalutamide (50 mg once daily) plus LHRH analogue therapy
Number of subjects: 813

Group type: COMPARATOR
Intervention: Flutamide (250 mg three times daily) plus LHRH analogue therapy
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Bicalutamide plus LHRH analogue therapy
Number of subjects: 813

Group type: COMPARATOR
Intervention: Flutamide plus LHRH analogue therapy
Number of subjects: 813
Study: 1835650

Group type: EXPERIMENTAL
Intervention: Norplant (levonorgestrel)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Injectable norethisterone enanthate
Number of subjects: 120

Group type: COMPARATOR
Intervention: IUD
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Vaginal ring releasing 10 mg of natural progesterone per 24 h
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Natural progesterone as a contraceptive
Number of subjects: 120
Study: 6217949

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (0.04 mg per dose, 3 times daily)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Salbutamol (0.2 mg per dose, 3 times daily)
Number of subjects: 43
Study: 31063869

Group type: EXPERIMENTAL
Intervention: Oxytocin in combination with Alcohol Behavioral Couples Therapy (ABCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo in combination with Alcohol Behavioral Couples Therapy (ABCT)
Number of subjects: 0
Study: 29194267

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (Group B)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (Group A)
Number of subjects: 22
Study: 26520160

Group type: EXPERIMENTAL
Intervention: Web-based intervention arm
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Overall recruitment strategy
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Postpartum recruitment
Number of subjects: 107
Study: 24747932

Group type: EXPERIMENTAL
Intervention: Care management intervention for PTSD
Number of subjects: 404

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 404
Study: 21355042

Group type: EXPERIMENTAL
Intervention: Caspofungin
Number of subjects: 32

Group type: COMPARATOR
Intervention: Amphotericin B
Number of subjects: 32
Study: 19095663

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Orlistat
Number of subjects: 40
Study: 17985808

Group type: EXPERIMENTAL
Intervention: Shamanic treatment during 5 treatment visits
Number of subjects: 23
Study: 16288823

Group type: EXPERIMENTAL
Intervention: Reach-to-grasp tasks of different levels of complexity
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Strongly lateralized children
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Less lateralized children
Number of subjects: 65
Study: 12700990

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with local anesthetics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early postoperative food intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Osmotic laxatives and prokinetic drugs (e.g., erythromycin, acetylcholinesterase inhibitors)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of epidural anesthesia, sparse use of i.v. opioids, early food intake, and laxatives/prokinetics
Number of subjects: 0
Study: 11011459

Group type: EXPERIMENTAL
Intervention: Doctors made aware of a prize
Number of subjects: 700

Group type: COMPARATOR
Intervention: Telephone call introduction
Number of subjects: 700

Group type: COMPARATOR
Intervention: Postcard introduction
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Female doctors
Number of subjects: 700

Group type: COMPARATOR
Intervention: Rural doctors
Number of subjects: 700

Group type: COMPARATOR
Intervention: Practice Assessment activity
Number of subjects: 700
Study: 8666632

Group type: EXPERIMENTAL
Intervention: Low-energy extracorporeal shock-wave therapy (3000 impulses of 0.08 mJ/mm2)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (30 impulses)
Number of subjects: 100
Study: 1632402

Group type: EXPERIMENTAL
Intervention: Benazepril (n = 114)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo (n = 58)
Number of subjects: 172
Study: 6660926

Group type: EXPERIMENTAL
Intervention: Org OD 14
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 30692052

Group type: EXPERIMENTAL
Intervention: Thymectomy plus prednisone
Number of subjects: 68

Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 68
Study: 29847684

Group type: EXPERIMENTAL
Intervention: Written patient admission and discharge evaluation method
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-fidelity simulation manikin evaluation method
Number of subjects: 0
Study: 27565831

Group type: EXPERIMENTAL
Intervention: Repeated exposure to recommended amounts of vegetables
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adding vegetables to the diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Substitution of vegetables in the diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Markers of bone turnover
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-reported secondary outcomes measured by questionnaire
Number of subjects: 0
Study: 24599578

Group type: COMPARATOR
Intervention: Standard dose of aerobic exercise (STAN; 25 to 30 minutes, thrice weekly)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Higher dose of aerobic exercise (HIGH; 50 to 60 minutes, thrice weekly)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Combined dose of aerobic and resistance exercise (COMB; 50 to 60 minutes, thrice weekly)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Standard dose of aerobic exercise (STAN)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Higher dose of aerobic exercise (HIGH) and Combined exercise (COMB)
Number of subjects: 301
Study: 23285019

Group type: EXPERIMENTAL
Intervention: High Protein (HP) diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low Protein (LP) diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal Protein (NP) diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fecal water genotoxicity
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Metabolite profiles
Number of subjects: 20
Study: 20233640

Group type: EXPERIMENTAL
Intervention: Stress day (cortisol measured pre- and post-stress)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rest day control (cortisol measured at the same time of day and for the same duration)
Number of subjects: 0
Study: 17949394

Group type: EXPERIMENTAL
Intervention: Nicotine-containing cigarettes
Number of subjects: 49

Group type: COMPARATOR
Intervention: Nicotine-free cigarettes
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Family history of alcoholism (FH+)
Number of subjects: 49
Study: 16230587

Group type: EXPERIMENTAL
Intervention: Meniett device
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 12390642

Group type: EXPERIMENTAL
Intervention: Melatonin treatment
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 9926949

Group type: EXPERIMENTAL
Intervention: Vastus muscle-splitting approach
Number of subjects: 100

Group type: COMPARATOR
Intervention: Median parapatellar approach
Number of subjects: 100
Study: 7753456

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMW heparin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unfractionated heparin (UF heparin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heptest assay from plasma samples
Number of subjects: 0
Study: 2196971

Group type: EXPERIMENTAL
Intervention: Intravenous indomethacin
Number of subjects: 116

Group type: COMPARATOR
Intervention: Rectal indomethacin
Number of subjects: 116
Study: 6782609

Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 27862055

Group type: EXPERIMENTAL
Intervention: SCORRE intervention (motivational video, LS7 risk assessment, 6-week behavioral diary)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 25920709

Group type: EXPERIMENTAL
Intervention: Concurrent radiotherapy (60 Gy over 6 weeks) and temozolomide (75 mg/m(2)), followed by six adjuvant 28‐day cycles of either dose‐dense (150 mg/m(2), days 1‐7, 15‐21) or metronomic (50 mg/m(2), days 1‐28) temozolomide, and maintenance RA (100 mg/m(2), days 1‐21/28) until disease progression.
Number of subjects: 31
Study: 25146067

Group type: EXPERIMENTAL
Intervention: Wet cupping combined with dietary advice
Number of subjects: 126

Group type: COMPARATOR
Intervention: Dietary advice alone (Control)
Number of subjects: 126
Study: 22030896

Group type: EXPERIMENTAL
Intervention: EGb 761 (120 mg two times a day)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: EGb 761
Number of subjects: 41
Study: 20232789

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 17464093

Group type: EXPERIMENTAL
Intervention: L-thyroxine therapy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (healthy young women)
Number of subjects: 31
Study: 15107657

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 0

Group type: COMPARATOR
Intervention: Citalopram
Number of subjects: 0
Study: 12434933

Group type: EXPERIMENTAL
Intervention: Low-intensity millimeter waves
Number of subjects: 0
Study: 9743274

Group type: EXPERIMENTAL
Intervention: Supraliminal target stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subliminal target stimuli
Number of subjects: 0

Group type: COMPARATOR
Intervention: Frequent stimuli
Number of subjects: 0
Study: 8066195

Group type: EXPERIMENTAL
Intervention: Integrated megavoltage imaging system for patient repositioning during radiotherapy
Number of subjects: 0
Study: 3289433

Group type: EXPERIMENTAL
Intervention: Prednisone followed by recombinant interferon alpha-2b
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 39
Study: 31084985

Group type: EXPERIMENTAL
Intervention: RIPCmultiple (daily RIPC for 6 days plus RIPC during 40 min before LPS), n=10
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: RIPCsingle (RIPC only during 40 min before LPS), n=10
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no RIPC before LPS), n=10
Number of subjects: 30
Study: 28284500

Group type: EXPERIMENTAL
Intervention: Baseline BNP
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Baseline BigET-1
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Relative changes in BNP after 1 month
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Relative changes in BigET-1 after 1 month
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Combined baseline and changes in BigET-1 with BNP
Number of subjects: 476
Study: 25788234

Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Replacement (TAVR)
Number of subjects: 699

Group type: COMPARATOR
Intervention: Surgical Aortic Valve Replacement (SAVR)
Number of subjects: 699
Study: 21907422

Group type: EXPERIMENTAL
Intervention: Candesartan 32 mg once daily on top of conventional treatment
Number of subjects: 91

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 91
Study: 21719107

Group type: EXPERIMENTAL
Intervention: Insulin glargine plus insulin glulisine (glargine/glulisine)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Premixed insulin analogues
Number of subjects: 197
Study: 18160344

Group type: EXPERIMENTAL
Intervention: Intervention (nurse-led lifestyle counselling and preparation for surgery at monthly intervals)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control
Number of subjects: 188
Study: 16822451

Group type: EXPERIMENTAL
Intervention: Aspirin and extended-release dipyridamole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin and a thieno-pyridine
Number of subjects: 0
Study: 14679093

Group type: EXPERIMENTAL
Intervention: Insulin (Ins group)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sulfonylurea (SU group)
Number of subjects: 54
Study: 15478858

Group type: EXPERIMENTAL
Intervention: Eradication of Helicobacter pylori infection
Number of subjects: 0
Study: 10424979

Group type: EXPERIMENTAL
Intervention: Composite material (Belle Glass)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ceramic material (SR Isosit)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fiber-reinforced composite material (Empress)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (unprepared teeth)
Number of subjects: 40
Study: 8688986

Group type: EXPERIMENTAL
Intervention: Erdosteine (300 mg x 2/day) with amoxycillin (1500 mg/day)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Placebo with amoxycillin (1500 mg/day)
Number of subjects: 237
Study: 2244610

Group type: EXPERIMENTAL
Intervention: Penicillin V potassium (40 to 50 mg/kg per day for 10 days)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Erythromycin estolate (30 to 40 mg/kg per day for 10 days)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Cephalexin monohydrate (40 to 50 mg/kg per day for 10 days)
Number of subjects: 73
Study: 403551

Group type: EXPERIMENTAL
Intervention: Diazepam (0.3 mg/kg)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Scopolamine (8 mug/kg)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Physostigmine (16 and 32 mug/kg)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Methscopolamine (8 and 16 mug/kg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 31196169

Group type: EXPERIMENTAL
Intervention: Enhanced Triple B for Baby (ETPB) plus care as usual (CAU)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Mellow Bumps (MB) plus care as usual (CAU)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 6
Study: 25682951

Group type: EXPERIMENTAL
Intervention: Provider/clinic-based recruitment
Number of subjects: 1228

Group type: EXPERIMENTAL
Intervention: Direct mail
Number of subjects: 1228

Group type: EXPERIMENTAL
Intervention: Brochures/flyers
Number of subjects: 1228

Group type: EXPERIMENTAL
Intervention: Web-based recruitment
Number of subjects: 1228

Group type: EXPERIMENTAL
Intervention: Word of mouth
Number of subjects: 1228
Study: 23893145

Group type: EXPERIMENTAL
Intervention: Nintendo Wii Fit Plus exercises
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional balance training program (T group)
Number of subjects: 40
Study: 21241460

Group type: EXPERIMENTAL
Intervention: 1 gram of polyunsaturated fatty acids
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 2 grams of polyunsaturated fatty acids
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 19128368

Group type: EXPERIMENTAL
Intervention: Rimonabant followed by Metformin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Metformin only
Number of subjects: 20
Study: 17563165

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Light therapy (LT)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Combined CBT + LT
Number of subjects: 61

Group type: COMPARATOR
Intervention: Minimal contact/delayed LT control (MCDT)
Number of subjects: 61
Study: 15459300

Group type: EXPERIMENTAL
Intervention: Caspofungin
Number of subjects: 1095

Group type: COMPARATOR
Intervention: Liposomal amphotericin B
Number of subjects: 1095
Study: 11437206

Group type: EXPERIMENTAL
Intervention: Dynamic chair with movable seat and back rest
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dynamic chair with freely movable seat and back rest
Number of subjects: 10

Group type: COMPARATOR
Intervention: Fixed chair with fixed seat and back rest
Number of subjects: 10
Study: 9709409

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no aspirin)
Number of subjects: 10
Study: 7976695

Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) - 30 mg weekly for one month, then monthly for one year
Number of subjects: 66

Group type: COMPARATOR
Intervention: Interferon Alpha 2B (IFN) - 50 million units weekly for 3 months, then monthly for one year
Number of subjects: 66
Study: 2736920

Group type: EXPERIMENTAL
Intervention: Ketanserin (KET)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sodium Nitroprusside (SNP)
Number of subjects: 26
Study: 29912570

Group type: EXPERIMENTAL
Intervention: CQR-300 (300 mg daily)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo (corn starch, 300 mg daily)
Number of subjects: 67
Study: 28284844

Group type: EXPERIMENTAL
Intervention: Low dose methotrexate (target dose: 15-20mg/week)
Number of subjects: 7000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7000
Study: 25967706

Group type: EXPERIMENTAL
Intervention: Boswellia-based cream (Bosexil(R))
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 23574582

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 21324563

Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 1409

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1409
Study: 19690523

Group type: EXPERIMENTAL
Intervention: Comprehensive self-management (CSM) delivered in person
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Comprehensive self-management (CSM) delivered primarily by telephone
Number of subjects: 188

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 188
Study: 17685703

Group type: EXPERIMENTAL
Intervention: CHO+P gel (0.15 g CHO + 0.038 g protein x kg BW(-1))
Number of subjects: 13

Group type: COMPARATOR
Intervention: CHO gel (0.15 g CHO x kg BW(-1))
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: CHO+P gel
Number of subjects: 13

Group type: COMPARATOR
Intervention: CHO gel
Number of subjects: 13
Study: 15228134

Group type: EXPERIMENTAL
Intervention: Japanese version of the Pulmonary Functional Status and Dyspnea Questionnaire (PFSDQ‐M)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Japanese version of the PFSDQ‐M
Number of subjects: 63
Study: 11494442

Group type: EXPERIMENTAL
Intervention: Gliclazide
Number of subjects: 30

Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 30
Study: 9623431

Group type: EXPERIMENTAL
Intervention: Intraoperative skin warming with a water mattress and forced warm air
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (conventional management without skin warming)
Number of subjects: 86
Study: 7868847

Group type: EXPERIMENTAL
Intervention: Zopiclone for 28 days
Number of subjects: 1507

Group type: COMPARATOR
Intervention: Flunitrazepam
Number of subjects: 1507

Group type: COMPARATOR
Intervention: Triazolam
Number of subjects: 1507

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1507
Study: 3339726

Group type: EXPERIMENTAL
Intervention: Doxorubicin twice weekly for 6 weeks
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Doxorubicin for 1 year
Number of subjects: 268

Group type: COMPARATOR
Intervention: No further treatment after transurethral resection
Number of subjects: 268
Study: 30091218

Group type: COMPARATOR
Intervention: SAR425899 (0.01-0.1 mg single ascending doses)
Number of subjects: 108

Group type: COMPARATOR
Intervention: SAR425899 (daily doses over 21 or 28 days)
Number of subjects: 108
Study: 27736032

Group type: EXPERIMENTAL
Intervention: High-dose unfractionated heparin (100 units kg-1 bolus)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Low-dose unfractionated heparin (50 units kg-1 bolus)
Number of subjects: 49
Study: 24402740

Group type: EXPERIMENTAL
Intervention: Inspiratory Resistive Muscle Training (IMT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Incentive Spirometry
Number of subjects: 30
Study: 23839107

Group type: EXPERIMENTAL
Intervention: CYD tetravalent dengue vaccine (TDV)
Number of subjects: 80
Study: 21172891

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) 3 mg/m² on day 1 of induction course 1 with various induction schedules
Number of subjects: 1113

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) in course 3 in combination with amsacrine, cytarabine, and etoposide or high-dose cytarabine
Number of subjects: 1113

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with GO
Number of subjects: 1113
Study: 16884899

Group type: EXPERIMENTAL
Intervention: Intervention group (extra support and education through group discussions)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60